References

  • Massion, P., Biomarkers to the Rescue in a Lung Nodule Epidemic. vol. 32 no. 8 p. 725-726.
  • Pastorino, U. et.al., Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012 May;21(3):308-15
  • Fortunato O. et. al., Assessment of Circulating microRNAs in Plasma of Lung Cancer Patients. Molecules 2014, 19, 3038-3054
  • Aberle, D., et al., National Lung Screening Trial Research, Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 2011. 365(5): p. 395-409.
  • Boeri, M., et al., MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A, 2011. 108(9): p. 3713-8.
  • Goulart, B., et al., Lung Cancer Screening With Low-Dose Computed Tomography: Costs, National Expenditures, and Cost-Effectiveness. J Natl Compr Canc Netw 2012; 10:267-275.
  • Humphrey, L., et al., Screening for lung cancer with low-dose computed tomography: a systematic review to update the U.S. Preventive services task force recommendation. Ann Intern Med, 2013. 159(6): p. 411-20.
  • Iorio, M. and C. Croce, MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med, 2012. 4(3): p. 143-59.
  • Zamore, P. and B. Haley, Ribo-gnome: the big world of small RNAs. Science, 2005. 309(5740): p. 1519-24.
  • Calin G., et. al., Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 inchronic lymphocytic leukemia. PNAS 2002 Nov 26;99(24) p.15524-9